KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Income from Non-Controlling Interests (2019 - 2025)

Historic Income from Non-Controlling Interests for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to $156.0 million.

  • Royalty Pharma's Income from Non-Controlling Interests fell 4054.45% to $156.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $537.7 million, marking a year-over-year decrease of 549.53%. This contributed to the annual value of $471.8 million for FY2024, which is 1652.78% down from last year.
  • According to the latest figures from Q3 2025, Royalty Pharma's Income from Non-Controlling Interests is $156.0 million, which was down 4054.45% from $60.5 million recorded in Q2 2025.
  • In the past 5 years, Royalty Pharma's Income from Non-Controlling Interests registered a high of $366.0 million during Q2 2021, and its lowest value of -$153.9 million during Q4 2022.
  • In the last 5 years, Royalty Pharma's Income from Non-Controlling Interests had a median value of $119.9 million in 2021 and averaged $118.8 million.
  • Per our database at Business Quant, Royalty Pharma's Income from Non-Controlling Interests tumbled by 43636.9% in 2022 and then soared by 225538.61% in 2025.
  • Royalty Pharma's Income from Non-Controlling Interests (Quarter) stood at $45.8 million in 2021, then tumbled by 436.37% to -$153.9 million in 2022, then soared by 245.02% to $223.2 million in 2023, then tumbled by 43.5% to $126.1 million in 2024, then grew by 23.67% to $156.0 million in 2025.
  • Its last three reported values are $156.0 million in Q3 2025, $60.5 million for Q2 2025, and $195.1 million during Q1 2025.